MCLAB

Executive Summary

Molecular Cloning Laboratories (MCLAB) is a privately held biotechnology company based in South San Francisco, founded in 1998. The company specializes in genetics, genomics, and diagnostics, offering a unique same-day Oxford Nanopore sequencing service for plasmids, amplicons, and bacterial genomes. This rapid turnaround positions MCLAB as a niche service provider for researchers and biotech firms requiring expedited sequencing results. Additionally, MCLAB supplies a broad portfolio of molecular biology reagents, including enzymes, cloning kits, gene editing tools, and protein purification products, catering to diverse laboratory needs. With over two decades of operation, MCLAB has established a stable presence in the competitive molecular biology market. Its dual revenue streams—sequencing services and reagent sales—provide a balanced business model. While the company remains private with no disclosed funding or valuation, its long-standing history suggests steady, organic growth. Future prospects may hinge on expanding its sequencing capabilities, launching new product lines, or forming strategic partnerships. However, given the lack of public catalysts, the near-term outlook is moderate.

Upcoming Catalysts (preview)

• Q3 2026Expansion of same-day sequencing to include long-read and whole-genome applications60% success
• 2026Strategic partnership with a major biopharma for custom reagent development40% success
• TBDLaunch of a direct-to-consumer genomics service or online sales platform expansion30% success